Amgen Inc. Debt Securities, Available-for-sale, Realized Loss
Amgen Inc. (AMGN) reported Debt Securities, Available-for-sale, Realized Loss of $4.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-09.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2021-04-28
- Amgen Inc. debt securities, available-for-sale, realized loss for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. debt securities, available-for-sale, realized loss for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. debt securities, available-for-sale, realized loss for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. debt securities, available-for-sale, realized loss for the quarter ending 2020-03-31 was $4.00M, a 20.00% decline year-over-year.
- Amgen Inc. debt securities, available-for-sale, realized loss for fiscal 2020 was $4.00M, a 88.89% decline from fiscal 2019.
- Amgen Inc. debt securities, available-for-sale, realized loss for fiscal 2019 was $36.00M, a 90.86% decline from fiscal 2018.
- Amgen Inc. debt securities, available-for-sale, realized loss for fiscal 2018 was $394.00M, a 84.98% increase from fiscal 2017.
- Amgen Inc. debt securities, available-for-sale, realized loss for fiscal 2017 was $213.00M, a 41.96% decline from fiscal 2016.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $0.00 derived: sum of 2 quarters · filed 2021-02-09 | $0.00 derived: sum of 3 quarters · filed 2021-02-09 | $4.00M 10-K · filed 2021-02-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $4.00M 10-Q · filed 2020-10-29 | $8.00M derived: sum of 4 quarters · filed 2021-04-28 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $4.00M 10-Q · filed 2020-07-29 | $8.00M derived: sum of 3 quarters · filed 2021-04-28 | $32.00M derived: sum of 4 quarters · filed 2021-04-28 |
| 2020-03-31 | $4.00M 10-Q · filed 2021-04-28 | $8.00M derived: sum of 2 quarters · filed 2021-04-28 | $32.00M derived: sum of 3 quarters · filed 2021-04-28 | $35.00M derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $28.00M derived: sum of 2 quarters · filed 2021-02-09 | $31.00M derived: sum of 3 quarters · filed 2021-02-09 | $36.00M 10-K · filed 2021-02-09 |
| 2019-09-30 | $24.00M 10-Q · filed 2020-10-29 | $27.00M derived: sum of 2 quarters · filed 2020-10-29 | $32.00M 10-Q · filed 2020-10-29 | $47.00M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $3.00M 10-Q · filed 2019-07-31 | $8.00M 10-Q · filed 2020-07-29 | $23.00M derived: sum of 3 quarters · filed 2021-02-09 | $131.00M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $5.00M 10-Q · filed 2020-05-01 | $20.00M derived: sum of 2 quarters · filed 2021-02-09 | $128.00M derived: sum of 3 quarters · filed 2021-02-09 | $248.00M derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $123.00M derived: sum of 2 quarters · filed 2021-02-09 | $243.00M derived: sum of 3 quarters · filed 2021-02-09 | $394.00M 10-K · filed 2021-02-09 |
| 2018-09-30 | $108.00M 10-Q · filed 2019-10-30 | $228.00M derived: sum of 2 quarters · filed 2019-10-30 | $379.00M 10-Q · filed 2019-10-30 | $409.00M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $120.00M 10-Q · filed 2019-07-31 | $271.00M 10-Q · filed 2019-07-31 | $301.00M derived: sum of 3 quarters · filed 2020-02-12 | $313.00M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $151.00M 10-Q · filed 2019-05-01 | $181.00M derived: sum of 2 quarters · filed 2020-02-12 | $193.00M derived: sum of 3 quarters · filed 2020-02-12 | $280.00M derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $42.00M derived: sum of 2 quarters · filed 2020-02-12 | $129.00M derived: sum of 3 quarters · filed 2020-02-12 | $213.00M 10-K · filed 2020-02-12 |
| 2017-09-30 | $12.00M 10-Q · filed 2018-10-31 | $99.00M derived: sum of 2 quarters · filed 2018-10-31 | $183.00M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $87.00M 10-Q · filed 2018-07-27 | $171.00M 10-Q · filed 2018-07-27 | ||
| 2016-12-31 | $367.00M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |